Published in Curr Pharm Des on January 01, 2007
Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol (2011) 2.14
Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg (2009) 1.34
Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. Brain Behav Immun (2010) 1.14
Plasma metabolomics and proteomics profiling after a postprandial challenge reveal subtle diet effects on human metabolic status. Metabolomics (2011) 1.06
Pleiotropic benefit of monomeric and oligomeric flavanols on vascular health--a randomized controlled clinical pilot study. PLoS One (2011) 0.97
Effect of psyllium fiber supplementation on C-reactive protein: the trial to reduce inflammatory markers (TRIM). Ann Fam Med (2008) 0.88
Kidney function and estimated vascular risk in patients with primary dyslipidemia. Open Cardiovasc Med J (2009) 0.79
The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance. Scientifica (Cairo) (2012) 0.79
Serum biomarkers VEGF-C and IL-6 are associated with severe human Peripheral Artery Stenosis. J Inflamm (Lond) (2015) 0.75
Cardiovascular risk assessment of South Asians in a religious setting: a feasibility study. Int J Clin Pract (2011) 2.12
Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes (1983) 1.90
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol (2004) 1.45
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol (1999) 1.43
Critique of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): flaws in CREST and its interpretation. Eur J Vasc Endovasc Surg (2013) 1.42
Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther (2003) 1.41
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. Atherosclerosis (2000) 1.39
Re: Effects of prostaglandin E1 on penile erection and erectile failure. J Urol (1988) 1.38
How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf (2009) 1.31
Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis (2009) 1.31
Effect of ethanol on vascular prostacyclin (prostaglandin I2) synthesis, platelet aggregation, and platelet thromboxane release. Br Med J (Clin Res Ed) (1983) 1.30
The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab (2005) 1.30
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab (2011) 1.28
Cardiotoxicity of 5-fluorouracil. Lancet (1977) 1.25
Platelet function defects in chronic alcoholism. Br Med J (Clin Res Ed) (1986) 1.23
Exocrine pancreatic function in diabetes mellitus. J Clin Pathol (1984) 1.22
Assessment of platelet function in patients with Raynaud's syndrome. J Clin Pathol (1984) 1.22
Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism (1983) 1.22
Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest (1988) 1.20
Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J (2011) 1.18
Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol (2013) 1.16
Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest (2005) 1.15
Pancreatic exocrine function after truncal and highly selective vagotomy. J Clin Pathol (1981) 1.15
An investigation into the effects of bacterial lipopolysaccharide on human platelets. Eur J Haematol (1989) 1.14
Mean Platelet Volume and Platelet Distribution Width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity? Platelets (2011) 1.14
Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res (1999) 1.12
The effects of fenfluramine on in vitro platelet aggregation. Br J Clin Pharmacol (1982) 1.12
Protection of prostacyclin-like activity in human plasma-a non-enzymatic mechanism? Clin Sci (Lond) (1982) 1.12
A thesis for all seasons. Nature (1991) 1.09
New developments in anti-platelet therapies: potential use of CD39/vascular ATP diphosphohydrolase in thrombotic disorders. Curr Drug Targets (2001) 1.07
Visceral leishmaniasis resembling systemic lupus erythematosus. Ann Rheum Dis (2004) 1.06
Adrenaline and potassium. Lancet (1984) 1.06
Prevention and treatment of the metabolic syndrome. Angiology (2004) 1.06
Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int (2008) 1.06
The effect of non-specific beta-blockade on metabolic and haemostatic variables during hypoglycaemia. Diabetes Res (1985) 1.03
Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev (2008) 1.03
Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens (2000) 1.02
Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. In Vivo (1993) 1.01
Experimental diabetes mellitus inhibits prostacyclin synthesis by the rat penis: pathological implications. Diabetologia (1985) 1.01
Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg (2001) 1.00
Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol (1984) 1.00
Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology (1987) 1.00
Warfarin administration increases uric acid concentrations in plasma. Clin Chem (1986) 0.98
Diagnosis and management of the metabolic syndrome in obesity. Obes Rev (2005) 0.98
Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets (2000) 0.98
Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets (2007) 0.97
Towards a doctoral thesis through published works. Biomed Pharmacother (1993) 0.97
Plasma creatinine and creatinine clearance in nutritional osteomalacia. Lancet (1984) 0.96
Tangier disease four decades of research: a reflection of the importance of HDL. Curr Med Chem (2006) 0.96
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids (2008) 0.96
Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins Leukot Med (1985) 0.96
Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev (2007) 0.95
Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev (2011) 0.95
Hypothermia and pancreatitis. J Clin Pathol (1983) 0.95
Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother (2008) 0.95
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis (2006) 0.95
Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc Res (2000) 0.94
The use of citrated whole blood in thromboelastography. Anesth Analg (2000) 0.94
Continuous infusion of N-acetylcysteine reduces liver warm ischaemia-reperfusion injury. Br J Surg (2004) 0.94
Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest (1985) 0.93
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab (2007) 0.93
Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev (2008) 0.93
Lipoprotein (a) and stroke. J Clin Pathol (2000) 0.92
Postprandial hypertriglyceridaemia in patients with Tangier disease. J Clin Pathol (2003) 0.92
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin (2005) 0.92
A review of the metabolic effects of sibutramine. Curr Med Res Opin (2005) 0.92
Excitatory receptor-prostanoid synthesis coupling in smooth muscle: mediation by calcium, protein kinase C and G proteins. Prostaglandins Leukot Essent Fatty Acids (1988) 0.92
Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol (2009) 0.92
Effect of diflunisal on in vitro platelet aggregation. Lancet (1980) 0.92
Thromboxane A2 analogue (U-46619) stimulates vascular PGI2 synthesis. Eur J Pharmacol (1985) 0.92
Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin (2003) 0.91
Is bilirubin protective against coronary artery disease? Clin Chem (1994) 0.91
Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med (2005) 0.91
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin (2008) 0.90
Adrenergic modulation of vascular prostacyclin (PGI2) secretion. Eur J Pharmacol (1985) 0.90
Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets (2006) 0.90
Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis (2006) 0.90
Nitric oxide in the lower urinary tract: physiological and pathological implications. BJU Int (2000) 0.90
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling. Curr Med Res Opin (2001) 0.89
Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol (1985) 0.89
Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease? Public Health (2013) 0.89
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr Metab Cardiovasc Dis (2011) 0.89
Do statins have an antiarrhythmic activity? Cardiovasc Res (2007) 0.89
Platelet hyperaggregability in cystic fibrosis. Prostaglandins Leukot Med (1987) 0.89
High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol (2009) 0.88
Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens (1999) 0.88
Periodontitis and abdominal aortic aneurysms: a random association or a pathogenetic link? Int Angiol (2009) 0.88
Heterozygote men with familial hypercholesterolaemia may have an abnormal triglyceride response post-prandially. Evidence for another predictor of vascular risk in familial hypercholesterolaemia. Int J Clin Pract (2005) 0.88
Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens (2004) 0.88
The effect of nifedipine, nimodipine and nisoldipine on agonist- and trauma-stimulated vascular prostacyclin synthesis in vitro. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.88
Effect of human plasma proteins on stabilisation of platelet anti-aggregatory activity of prostacyclin. Ann Clin Biochem (1982) 0.88
Fibrates: therapeutic potential for diabetic nephropathy? Eur J Intern Med (2012) 0.88